A Chat with Orlando Agrippa, Founder and CEO at Health Tracking Data Platform: Sanius Health

Sanius Health is a patient-generated health data tracking platform dedicated to improving the lives and wellbeing of people living with rare diseases – which are often, by their very nature, little understood – through better management of their conditions and symptoms.

We do so through the use of wearable technologies and AI-driven digital innovation. This allows Sanius Health to collect valuable, real-time insights from patients, in turn using its advanced digital platform and ecosystem to advance research into care and chronic conditions.

This paves the way for more effective treatments and tailored approaches to care that will ultimately enhance patients’ quality of life and provide them with ownership of their overall health outcomes.


What do you think makes this company unique?

What sets Sanius Health apart is our drive and ambition to address the lack of data on rare diseases. Our approach is particularly prevalent when it comes to Sickle Cell Disease (SCD), which millions of people live with worldwide, meaning that there’s a growing need for tangible data-driven and digital solutions. From our experience, the key to advancing SCD care is through the utilisation of technologies that can provide detailed, real-time and actionable data to patients and clinicians to help them predict and manage their symptoms.

Sanius Health leads the charge when it comes to understanding this complex condition, by using machine learning to analyse large amounts of data from consented patient medical records, patient surveys and other sources to identify patterns and trends that can be used to predict and prevent complications from rare diseases.

How has the company evolved over the last couple of years?

Our patient ecosystem has expanded over time beyond its primary focus on SCD to include other conditions such as a rare blood cancer called Waldenstrom macroglobulinemia, as well as Amyloidosis, which affects the body’s organs, neurological disorder Fabry and chronic myeloid leukaemia.

We have achieved this by forging partnerships with a wide network of NHS providers, charities, treatment centres, researchers, developers of therapeutics and regulators to advance outcomes for patients to build a truly comprehensive and unique picture of the UK’s health and rare diseases landscape. This has resulted in the number of patients joining the Sanius Health ecosystem increasing from 200 to 1,000, while the team has grown, with significant hires including an experienced consultant haematologist and haematology specialist pharmacist.

What can we hope to see from Sanius Health in the future?

We plan to expand internationally into new territories, including the US, India and the Middle East over the next 12 to 24 months. We also hope to further grow our user base and expert team throughout 2023 and beyond to continue in our mission to help as many patients as possible who live with rare diseases, when they need it the most.